Global Tubeless Insulin Pump Market is valued at USD 1.58 Billion in 2021 and is expected to reach USD 6.35 Million by 2028 with a CAGR of 21.93% over the forecast period.
Escalating the prevalence of diabetes and obesity, the growing geriatric population, and technological advancement in tubeless insulin delivery are some factors driving the growth of the market.
Insulin Pump which is also referred to as continuous subcutaneous insulin infusion is rapidly gaining popularity across the medical device industry. This medical device makes use of a near-physiologic basal-bolus procedure for the delivery of insulin and it is a flexible as well as lifestyle-friendly method. Insulin pump without tubing (patch pump), Tubeless patch pumps contain the insulin reservoir and the infusion cannula and adhere directly to the skin. A handheld device is used to program insulin delivery and insert the infusion cannula. This tubeless patch pump (pod) is operated by a handheld device called the “PDM” that is wirelessly connected to Bluetooth.
Moreover, tubeless insulin pumps are tiny, unobtrusive, and lightweight in nature and are also referred to as insulin patch pumps. These products are discrete, cost-effective, easily adhere to human skin, and easy to use. Currently, these pumps make use of nitinol wire, spring, step motor, piezoelectric crystal, manual pumping chamber, and bladder for insulin delivery. These tubeless insulin pumps are available in myriad sizes and technologies. These products can be worn and effectively handled under clothing.
With mounting cases of diabetes, especially among geriatric patients, the tubeless insulin pump market is estimated to witness significant growth over the forecast period. According to American Diabetes Association, In 2018, 34.2 million Americans, or 10.5% of the population, had diabetes. Almost 1.6 million Americans have type 1 diabetes, including about 187,000 children and adolescents. Additionally, the Development of novel insulin delivery devices will further boost the market growth. Lightweight and disposable pod such as Omnipod, by Ypsomed, endlessly deliver insulin for up to three days and is connected with a remote to conclude insulin delivery intervals. Correspondingly, in March 2019, the United States FDA gave fast-track title to EoPancreas, an Automated Insulin Delivery (AID) system, by EoFlow. However, partial reimbursement for tubeless insulin pumps and the drastically rising cost of insulin delivery systems may hinder the market growth in forthcoming years. Moreover, new products to the product line and the constant addition of new features to the existing products will boost the market opportunity over the coming years.
|2018 - 2021
|2022 - 2028
|Market Size in 2021:
|USD 1.58 Billion
|Base year considered
|Forecast Period CAGR %:
|Market Size Expected in 2028:
|USD 6.35 Billion
|Tables, Charts & Figures:
|Tubeless Insulin Pump Companies
|Insulet Corporation, Johnson & Johnson, Medtrum Technologies, Cellnova, Roche Holdings, Spring Health Solutions, Debiotech, CeQur, Valeritas Holding, Abbott Diabetes Care, Medtronic Plc., Tandem Diabetes Care, Insulet Corporation, Animas Corporation, Others
|By Component, By Distribution Channel
|North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa
North America dominates the tubeless insulin pumps market, due to factors such as the rising population base suffering from diabetes as well as increasing spending on insulin uptake per person will highly impact the demand for the tubeless insulin pump market in this region. According to Canadian Community Health Survey, in 2017, 7.3% of Canadians aged 12 and older (roughly 2.3 million people) reported being diagnosed with diabetes. In addition, new product launches and continuous up-gradation in technology will expand market growth in the forecast period.
Asia-Pacific is expected to be the highest growing region due to increasing government initiatives to enhance awareness about effective diabetes management. For example, the Australian Ministry of Health funded 100 million for extending promotional action of insulin, in the year 2018. The project provides fully subsidized insulin monitor devices to patients age below 21 years of age that are affected with diabetes. Hence, increasing government initiatives and diabetes care awareness among patients will raise the demand for the tubeless insulin pump market in this region.
Global tubeless insulin pump market is segmented on the basis of component, distribution channel, and region. On the basis of components, the market is segmented into pod/patch, remote, and others. On the basis of distribution channels, the market is segmented into hospitals, pharmacies, e-commerce, and others.
Middle East and Africa
We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us firstname.lastname@example.orgJOIN US
BrandEssence® Market Research and Consulting Pvt ltd.
124, City Road, London EC1V 2NX
© Copyright 2024-25 BrandEssence® Market Research and Consulting Pvt ltd. All Rights Reserved | Designed by BrandEssence®